Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.43 |
| ▸ | TUBB | P07437 | 2/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.43 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.43 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.43 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.43 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12552993 | 0.88 | SRC (0.49) | MAPTHPGDALDH1A1MAPK1TTR | |
| SCHEMBL30122857 | 0.88 | ALDH1A1 (0.63) | MAPTHPGDALDH1A1MAPK1PRKDC | |
| SCHEMBL524712 | 0.88 | ALDH1A1 (0.63) | MAPTHPGDALDH1A1MAPK1PRKDC | |
| SCHEMBL13429946 | 0.86 | ALDH1A1 (0.47) | MAPTHPGDALDH1A1MAPK1TTR | |
| SCHEMBL31132205 | 0.86 | TPMT (0.54) | MAPTHPGDALDH1A1MAPK1CA2 | |
| SCHEMBL5759025 | 0.86 | ALDH1A1 (0.47) | MAPTHPGDALDH1A1MAPK1TTR | |
| SCHEMBL2807788 | 0.86 | TPMT (0.54) | MAPTHPGDALDH1A1MAPK1CA2 | |
| SCHEMBL31063093 | 0.86 | ALDH1A1 (0.47) | MAPTHPGDALDH1A1MAPK1TTR | |
| SCHEMBL14958356 | 0.86 | ALDH1A1 (0.61) | MAPTHPGDALDH1A1MAPK1PRKDC | |
| SCHEMBL31063149 | 0.86 | ALDH1A1 (0.47) | MAPTHPGDALDH1A1MAPK1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183365-B2 | Synthetic method for ceratamine A and B and analogs thereof | THE OHIO STATE UNIVERSITY (US) | 2012-05-22 | — | — | US | claimed |
| US-20100234588-A1 | SYNTHETIC METHOD FOR CERATAMINE A AND B AND ANALOGS THEREOF | THE OHIO STATE UNIVERSITY (US) | 2010-09-16 | — | — | US | claimed |
| US-20260109674-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | THE UNIVERSITY OF TOLEDO (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| CN-116621897-B | Scopolamine derivatives, preparation method and medical application thereof | 中国药科大学 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024102245-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | THE UNIVERSITY OF TOLEDO (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4351560-A1 | ANTICANCER COMPOUNDS | The Regents of the University of California (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794525-A | Anticancer compounds | 加利福尼亚大学董事会 | 2024-03-29 | — | — | CN | disclosed |
| CN-114539249-B | Podophyllotoxin derivative tubulin inhibitor, and preparation method and medical application thereof | 中国药科大学 | 2024-01-26 | — | — | CN | disclosed |
| CN-116621897-A | Scopolamine derivatives, preparation method and medical application thereof | 中国药科大学 | 2023-08-22 | — | — | CN | disclosed |
| EP-2566851-A1 | COMBRETASTATIN ANALOGS FOR USE IN THE TREATMENT OF CANCER | Universität Bayreuth (DE) | 2013-03-13 | — | — | EP | disclosed |
| US-8183365-B2 | Synthetic method for ceratamine A and B and analogs thereof | THE OHIO STATE UNIVERSITY (US) | 2012-05-22 | — | — | US | disclosed |
| WO-2011138409-A1 | COMBRETASTATIN ANALOGS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITÄT BAYREUTH (DE) | 2011-11-10 | — | — | WO | disclosed |
| CN-101240166-B | Bromobenzothiazoles luminous agent and preparation method thereof | UNIV JIANGNAN | 2010-09-29 | — | — | CN | disclosed |
| US-20100234588-A1 | SYNTHETIC METHOD FOR CERATAMINE A AND B AND ANALOGS THEREOF | THE OHIO STATE UNIVERSITY (US) | 2010-09-16 | — | — | US | disclosed |
| CN-101240166-A | Bromobenzothiazoles luminous agent and preparation method thereof | UNIV JIANGNAN (CN) | 2008-08-13 | — | — | CN | disclosed |
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | MAPT 4800/4885HPGD 4399/4885ALDH1A1 2470/4885 |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | MAPT 2666/4885HPGD 3850/4885ALDH1A1 3346/4885 |
| US-20100234588-A1 | SYNTHETIC METHOD FOR CERATAMINE A AND B AND ANALOGS THEREOF | NR0B2, NR2C2, HRH3 | MAPT 4863/4885HPGD 2140/4885ALDH1A1 1875/4885 |
| US-20260109674-A1 | ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY | CHRM5, CHRM3, CHRNA3 | MAPT 621/4885HPGD 3634/4885ALDH1A1 2558/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | MAPT 2666/4885HPGD 3850/4885ALDH1A1 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.